О. О. Гордеева
Federal Research and Clinical Center of Physical-Chemical Medicine named after Y.M. Lopukhin · 37 works · 69 citations · h-index 4
Top works
- Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status
- Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
- Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?
- The effectiveness, safety and economic rationality of the neoadjuvant chemotherapy with biosimilar of Trastuzumab in HER2+ breast cancer in Russian clinical practice.
- Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
- Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0
- The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
- Role of clustered amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer
- The relationship of markers of early and late lymphocytes activation with the efficiency of neoadjuvant chemotherapy in triple negative breast cancer patients
- Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
- ASSOCIATION OF NKT- AND ACTIVATED CD25+ PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
- Ramucirumab in the treatment of refractory metastatic gastric cancer: Results from the RamSelGa trial
- Peripheral blood CD8+-lymphocytes populations and its value for direct and outlying treatment results in triple negative breast cancer patients
- REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE
- Ribociclib in 1st line HR+ breast cancer treatment
- Combined anti‑HER2 and hormonal treatment in a patient with HR+HER2+ clear‑cell uterine carcinoma: A case report
- Characteristics of metastatic lobular breast cancer
- Immunological predictive and prognostic factors in patients with stage II-III triple negative breast cancer.
- HER2 cluster amplification as a factor of an especial sensitivity for anti-HER2 neoadjuvant therapy with biosimilar of trastuzumab in Russian women with breast cancer stage II-III.
- Abstract 5975: Long-acting G-CSF empefilgrastim with dose-dense chemotherapy for patients with stage II-III TNBC: Defendor Special trial, primary analysis